Huge increase in PrEP uptake when services offer choice and flexibility, African studies show
San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Sharing anti-HIV medication is common in rural Uganda
Thai government shuts down key-population led PrEP services
Cabotegravir long-acting PrEP out of reach for upper middle-income nations
African migrants living in France less likely to benefit from antiretroviral innovations than people born in France
Not counted: clinical trials of new HIV treatments are failing women
Patient engagement can improve HIV care in the Caribbean
Passports and privilege: what does the future hold for global HIV conferences?
